Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

EMD licenses Luminex technology to develop assays for the xMAP platform
December 2007
SHARING OPTIONS:

GIBBSTOWN, N.J.-The Novagen brand of EMD Chemicals, a subsidiary of Merck KGaA, Darmstadt, Germany, announced that it has obtained a license from Luminex Corp. to develop immunoassays for the xMAP Technology platform. EMD/Merck is engaged in the development, manufacture and distribution of a broad array of research tools used for life science research and will create multiplex immunoassays using xMAP Technology to meet the evolving needs of drug discovery and cell signaling researchers.
 "The advantages of multiplex protein analysis are well established," says Lisa Johnson, VP of corporate development with EMD. "The Luminex xMAP platform has been instrumental in broadening the adoption of multiplex analysis."

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.